We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Q1 Potential of ResMed (RMD): Exploring Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Analysts on Wall Street project that ResMed (RMD - Free Report) will announce quarterly earnings of $2.67 per share in its forthcoming report, representing an increase of 4.7% year over year. Revenues are projected to reach $1.39 billion, increasing 4.2% from the same quarter last year.
The consensus EPS estimate for the quarter has undergone a downward revision of 0.8% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific ResMed metrics that are commonly monitored and projected by Wall Street analysts.
Analysts forecast 'Global revenue- Total Sleep and Breathing Health' to reach $1.25 billion. The estimate indicates a change of +6.8% from the prior-year quarter.
The average prediction of analysts places 'Global revenue- Residential Care Software' at $144.46 million. The estimate suggests a change of -13% year over year.
According to the collective judgment of analysts, 'Global revenue- Total Devices' should come in at $714.50 million. The estimate indicates a year-over-year change of +5%.
Analysts expect 'Global revenue- Total Masks and other' to come in at $535.83 million. The estimate indicates a year-over-year change of +9.6%.
The combined assessment of analysts suggests that 'Americas- Devices' will likely reach $434.08 million. The estimate suggests a change of +5% year over year.
The consensus estimate for 'Americas- Masks and other' stands at $393.72 million. The estimate suggests a change of +9% year over year.
Analysts' assessment points toward 'Rest of World- Total' reaching $429.11 million. The estimate indicates a year-over-year change of +8.7%.
The consensus among analysts is that 'Rest of World- Devices' will reach $285.55 million. The estimate indicates a year-over-year change of +7%.
Analysts predict that the 'Rest of World- Masks and other' will reach $143.57 million. The estimate indicates a year-over-year change of +12.3%.
Based on the collective assessment of analysts, 'Americas- Total' should arrive at $827.81 million. The estimate points to a change of +6.8% from the year-ago quarter.
Shares of ResMed have demonstrated returns of +12.6% over the past month compared to the Zacks S&P 500 composite's -0.2% change. With a Zacks Rank #3 (Hold), RMD is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Unlocking Q1 Potential of ResMed (RMD): Exploring Wall Street Estimates for Key Metrics
Analysts on Wall Street project that ResMed (RMD - Free Report) will announce quarterly earnings of $2.67 per share in its forthcoming report, representing an increase of 4.7% year over year. Revenues are projected to reach $1.39 billion, increasing 4.2% from the same quarter last year.
The consensus EPS estimate for the quarter has undergone a downward revision of 0.8% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific ResMed metrics that are commonly monitored and projected by Wall Street analysts.
Analysts forecast 'Global revenue- Total Sleep and Breathing Health' to reach $1.25 billion. The estimate indicates a change of +6.8% from the prior-year quarter.
The average prediction of analysts places 'Global revenue- Residential Care Software' at $144.46 million. The estimate suggests a change of -13% year over year.
According to the collective judgment of analysts, 'Global revenue- Total Devices' should come in at $714.50 million. The estimate indicates a year-over-year change of +5%.
Analysts expect 'Global revenue- Total Masks and other' to come in at $535.83 million. The estimate indicates a year-over-year change of +9.6%.
The combined assessment of analysts suggests that 'Americas- Devices' will likely reach $434.08 million. The estimate suggests a change of +5% year over year.
The consensus estimate for 'Americas- Masks and other' stands at $393.72 million. The estimate suggests a change of +9% year over year.
Analysts' assessment points toward 'Rest of World- Total' reaching $429.11 million. The estimate indicates a year-over-year change of +8.7%.
The consensus among analysts is that 'Rest of World- Devices' will reach $285.55 million. The estimate indicates a year-over-year change of +7%.
Analysts predict that the 'Rest of World- Masks and other' will reach $143.57 million. The estimate indicates a year-over-year change of +12.3%.
Based on the collective assessment of analysts, 'Americas- Total' should arrive at $827.81 million. The estimate points to a change of +6.8% from the year-ago quarter.
View all Key Company Metrics for ResMed here>>>Shares of ResMed have demonstrated returns of +12.6% over the past month compared to the Zacks S&P 500 composite's -0.2% change. With a Zacks Rank #3 (Hold), RMD is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .